H
Hatim Sati
Researcher at Pan American Health Organization
Publications - 11
Citations - 245
Hatim Sati is an academic researcher from Pan American Health Organization. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 3, co-authored 4 publications receiving 45 citations.
Papers
More filters
Journal ArticleDOI
Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings.
Mentor Ali Ber Lucien,Michael F. Canarie,Paul E. Kilgore,Gladzdin Jean-Denis,Natael Fenelon,Manise Pierre,Mauricio Cerpa,Gerard A. Joseph,Gina Maki,Marcus J. Zervos,Patrick Dely,Jacques Boncy,Hatim Sati,Ana del Rio,Pilar Ramon-Pardo +14 more
TL;DR: In this paper, the authors evaluated the worldwide evolution of antimicrobial resistance during the COVID-19 pandemic, because pathogens do not respect borders, and this issue takes on even greater importance in developing countries, where data on resistance patterns are scarce, conditions for infectious pathogen transmission are optimal, and treatment resources are suboptimal.
Journal ArticleDOI
Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed
Mark S. Butler,Valeria Gigante,Hatim Sati,Sarah Paulin,Laila Al-Sulaiman,John H. Rex,Prabhavathi Fernandes,Cesar A. Arias,Mical Paul,Guy E. Thwaites,Lloyd George Czaplewski,Richard A. Alm,Christian Lienhardt,Melvin Spigelman,Lynn L. Silver,Norio Ohmagari,Roman S. Kozlov,Stéphan Juergen Harbarth,Peter Beyer +18 more
TL;DR: Future antibacterial research and development (R&D) should focus on the development of innovative and clinically differentiated candidates that have clear and feasible progression pathways to the market, especially against critical-priority pathogens.
Journal ArticleDOI
Characterizing Shigella species distribution and antimicrobial susceptibility to ciprofloxacin and nalidixic acid in Latin America between 2000-2015.
Hatim Sati,Nienke Bruinsma,Marcelo Galas,Jenny Hsieh,Antonio Sanhueza,Pilar Ramon Pardo,Marcos A. Espinal +6 more
TL;DR: There is an increasing trend in Shigella nonsusceptibility to ciprofloxacin and NA, including among the most common shigella species, in Latin America, which is alarming and threatens the control and management of this currently treatable infection.
Journal ArticleDOI
The WHO Essential Medicines list AWaRe book: from a list to a quality improvement system.
Michael J. Sharland,V. Zanichelli,Loice Ombajo,Joel Bazira,Bernadette Cappello,Ronald Chitatanga,Pem Chuki,Sumanth Gandra,Haileyesus Getahun,Stéphan Juergen Harbarth,Mark Loeb,Marc Mendelson,Lorenzo Moja,Céline Pulcini,Hatim Sati,Evelina Tacconelli,Mei-wen Zeng,Benedikt Huttner +17 more
TL;DR: The AWaRe (AccessWatchReserve) as discussed by the authors is a system developed by WHO to classify antibiotics based on their spectrum of activity and potential for favouring the development of antibiotic resistance.
Journal ArticleDOI
The WHO AWaRe (Access, Watch, Reserve) antibiotic book and prevention of antimicrobial resistance
V. Zanichelli,Mike Sharland,Bernadette Cappello,Lorenzo Moja,Haileyesus Getahun,Carmem L Pessoa-Silva,Hatim Sati,Catharina Van Weezenbeek,H. O. Balkhy,Mariangela Simão,Sumanth Gandra,Benedikt Huttner +11 more
TL;DR: The AWaRe (Access, Watch, Reserve) antibiotic book as discussed by the authors provides guidance on the empiric use of antibiotics in the model lists with a strong emphasis on the AWARe framework, which is centred around the risk of antimicrobial resistance development associated with the use of different antibiotics.